MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patientsMathilde Saint‐Ghislain, Manuel Rodrigues, Yannick Le Corre et al.|European Journal of Cancer|2022Cited by 37
Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspManuel Rodrigues, Shufang Renault, Toulsie Ramtohul et al.|Nature Communications|2024Cited by 30
<i>MBD4</i> deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients: A retrospective study.Mathilde Saint‐Ghislain, Manuel Rodrigues, Lionnel Geoffrois et al.|Journal of Clinical Oncology|2022Cited by 2
Tebentafusp (tebe) in a real-world cohort of 72 French metastatic uveal melanoma (UM) patients (pts).Sophie Piperno‐Neumann, Manuel Rodrigues, Léah Mailly-Giacchetti et al.|Journal of Clinical Oncology|2023Cited by 1